Literature DB >> 15961283

The ketogenic diet influences the levels of excitatory and inhibitory amino acids in the CSF in children with refractory epilepsy.

Maria Dahlin1, Ase Elfving, Urban Ungerstedt, Per Amark.   

Abstract

The ketogenic diet (KD) is an established treatment for medically refractory pediatric epilepsy. Its anticonvulsant mechanism is still unclear. We examined the influence of the KD on the CSF levels of excitatory and inhibitory amino acids in 26 children (mean age 6.1 years) with refractory epilepsy. Seventeen amino acids were determined before and at a mean of 4 months after the start of the KD. Seizures were quantified. Highly significant changes were found in eight amino acids: increases in GABA, taurine, serine, and glycine and decreases in asparagine, alanine, tyrosine and phenylalanine. However, aspartate, glutamate, arginine, threonine, citrulline, leucine, isoleucine and valine/methionine remained unchanged. A significant correlation with seizure response was found for threonine (P=0.016). The GABA levels were higher in responders (>50% seizure reduction) than in nonresponders during the diet (P=0.041). In the very good responders (>90% seizure reduction), the GABA levels were significantly higher at baseline as well as during the diet. Age differences were found with significantly larger decreases in glutamate and increases in GABA in connection with the diet in younger children. Our results indicate that the KD significantly alters the levels of several CSF amino acids that may be involved in its mechanism of action and the increase in GABA is of particular interest.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961283     DOI: 10.1016/j.eplepsyres.2005.03.008

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  43 in total

Review 1.  Ketone bodies in epilepsy.

Authors:  Melanie A McNally; Adam L Hartman
Journal:  J Neurochem       Date:  2012-02-07       Impact factor: 5.372

Review 2.  State of the ketogenic diet(s) in epilepsy.

Authors:  Jennifer Huffman; Eric H Kossoff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

3.  The ketogenic diet increases Neuregulin 1 expression via elevating histone acetylation and its anti-seizure effect requires ErbB4 kinase activity.

Authors:  Jin Wang; Jie Huang; Shan Yao; Jia-Hui Wu; Hui-Bin Li; Feng Gao; Ying Wang; Guo-Bin Huang; Qiang-Long You; Jianhua Li; Xiaohui Chen; Xiang-Dong Sun
Journal:  Cell Biosci       Date:  2021-05-21       Impact factor: 7.133

Review 4.  Metabolism and epilepsy: Ketogenic diets as a homeostatic link.

Authors:  Susan A Masino; Jong M Rho
Journal:  Brain Res       Date:  2018-06-06       Impact factor: 3.252

Review 5.  Ketogenic diets, mitochondria, and neurological diseases.

Authors:  Lindsey B Gano; Manisha Patel; Jong M Rho
Journal:  J Lipid Res       Date:  2014-05-20       Impact factor: 5.922

Review 6.  β-Hydroxybutyrate: A Signaling Metabolite.

Authors:  John C Newman; Eric Verdin
Journal:  Annu Rev Nutr       Date:  2017-08-21       Impact factor: 11.848

Review 7.  Do ketone bodies mediate the anti-seizure effects of the ketogenic diet?

Authors:  Timothy A Simeone; Kristina A Simeone; Carl E Stafstrom; Jong M Rho
Journal:  Neuropharmacology       Date:  2018-01-08       Impact factor: 5.250

8.  Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome.

Authors:  M R Pranzatelli; E D Tate; J M Crowley; B Toennies; M Creer
Journal:  Neuropediatrics       Date:  2008-11-07       Impact factor: 1.947

Review 9.  Neurotransmitter modulation by the gut microbiota.

Authors:  Philip Strandwitz
Journal:  Brain Res       Date:  2018-08-15       Impact factor: 3.252

10.  Methyl ethyl ketone blocks status epilepticus induced by lithium-pilocarpine in rats.

Authors:  Osamu Inoue; Eriko Sugiyama; Nobuyoshi Hasebe; Noriko Tsuchiya; Rie Hosoi; Masatoshi Yamaguchi; Kohji Abe; Antony Gee
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.